Nucleoside compounds and uses thereof

• US 20040002596A1
• Filed: 12/13/2002
• Published: 01/01/2004
• Est. Priority Date: 06/16/2000
• Status: Active Grant

• Current Assignee: Valeant Research & Development (Bausch Health Cos., Inc.)
• Original Assignee: Valeant Research & Development (Bausch Health Cos., Inc.)
• Inventors: Girardet, Jean-Luc, Hong, Zhi, Lau, Johnson, Ramasamy, Kanda
• Granted Patent: US 6,815,542 B2
• Time in Patent Office: Days
• US Class Current: 536/26.9
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: C07H 19/052 Imidazole radicals
• CPC Class Codes: C07H 19/056 Triazole or tetrazole radicals

Abstract

Nucleosides, novel nucleoside analog compounds and their novel prodrug forms are disclosed. The novel compounds, prodrugs, or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.

Claims

1. A nucleoside analog of Formula 1, in which the sugar is either in the L- or D-configuration:

2. A nucleoside analog of Formula 2, in which the sugar is either in the L- or D-configuration:

3. The nucleoside analog of claim 2 having a structure according to Formula 3:

4. A nucleoside analog of Formula 4, in which the sugar is either in the L- or D-configuration:

5. A nucleoside analog of Formula 5, in which the sugar is either in the L- or D-configuration:

6. A nucleoside analog of Formula 6, in which the sugar is either in the L- or D-configuration: